| Document |
Document Title |
|
WO/2009/061744A2 |
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (K...
|
|
WO/2009/058810A1 |
The present invention is directed to processes for the preparation of substituted 2, 4, 5, 6, 7, 8 - hexahydro -1, 2, 6 - triaza-azulene derivatives of formula (I) and (II), useful for the treatment of disease states mediated by serotoni...
|
|
WO/2009/054983A1 |
The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involve...
|
|
WO/2009/051747A1 |
This invention relates to novel compounds that are 3-benzazepine derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 3-benzazepine derivatives that are derivatives of lorcaserin. ...
|
|
WO/2009/047796A1 |
The present invention relates to novel polymorphs of imipramine salts and the processes for their preparation.
|
|
WO/2009/023664A2 |
In its many embodiments, the present invention relates to a novel class of substituted azepine- and diazepine-sulfonamide compounds useful to inhibit 11BETA-hydroxysteroid dehydrogenase type-1, pharmaceutical compositions containing the ...
|
|
WO/2009/023453A1 |
Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described.
|
|
WO/2009/021758A1 |
The present invention relates to compounds of the general formula (I) in which A, B, D, Y, R1, R2, R3, R4 and R5 are as defined in claim 1, the enantiomers thereof, the diastereomers thereof, the mixtures thereof and the salts thereof, e...
|
|
WO/2009/016390A1 |
The invention relates to 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.
|
|
WO/2009/013299A2 |
The present invention relates to compounds of the general formula (I), in which A, Y, R1, R2, R3, R4 and R5 are as defined in claim 1, the enantiomers thereof, the diastereomers thereof, mixtures thereof and salts thereof, especially phy...
|
|
WO/2009/015004A1 |
The present invention provides crystal forms of (2-amino-4, 5,6,7- tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone of the formula: Formula (I); processes for the production of such crystal forms; pharmaceutical compositions com...
|
|
WO/2008/146308A9 |
The present invention encompasses a process for the preparation of highly pure ivabradine hydrochloride by treating ivabradine with alcoholic hydrogen chloride. The invention further encompasses amorphous ivabradine hydrochloride and pro...
|
|
WO/2009/001817A1 |
Disclosed is a compound having an excellent 11β-HSD1 inhibitory activity. Specifically disclosed is a compound represented by the following formula (I). (I) (In the formula (I), X1 represents an oxygen atom, a group expressed as -(CR11R...
|
|
WO/2009/001968A1 |
The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is r...
|
|
WO/2008/154347A1 |
The present invention is directed to a compound of Formula (I) or a form thereof: wherein U, V, W and Ring A are as defined herein, useful as vasopressin receptor antagonists.
|
|
WO/2008/150842A1 |
The invention relates to an ionic liquid composition and a method for preparing the ionic liquid. The ionic liquid comprises a cation containing the Formula I, disclosed, and wherein: n is 1 or 2, R1 is selected from the group consisting...
|
|
WO/2008/150954A1 |
Methods and compounds are disclosed for treating dry age-related macular degeneration, and preventing or delaying the onset of wet age-related macular degeneration.
|
|
WO/2008/141082A1 |
The aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepine derivative compounds of the present invention are represented by formulae (I) (A-E) having the following structure where the carbon atom designated * is in the R or S confi...
|
|
WO/2008/141081A1 |
The aryl- and heteroaryl-substituted tetrahydrobenzo-l,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R1 -R8 are as defined herein.
|
|
WO/2008/135524A2 |
The present invention relates to substituted anthranilamides of general formula (I), wherein D, M, A4, A5, R2, R3, R4and R6 are defined as in the specification. The compounds have an antithrombotic and a factor Xa inhibiting activity.
|
|
WO/2008/125006A1 |
A novel preparation process for ivabradine which is the medicine for angina pectoris, wherein compound III is obtained from compound II by catalytic hydrogenation, and then compound III is alkylated with compound IV to obtain compound I....
|
|
WO/2008/116308A1 |
The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS...
|
|
WO/2008/108639A1 |
The present invention provides a novel crystalline form of a cocrystal of carbamazepine : glycolamide and of a co-crystal of carbamazepine : lactamide. The invention further provides methods for the preparation of a co-crystal of carbama...
|
|
WO/2008/104589A1 |
The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders.
|
|
WO/2008/105445A1 |
Disclosed is a transdermal pharmaceutical composition characterized by blending eptazocine hydrobromide with a fatty acid ester, a glycerin fatty acid ester and a glycol or a pyrrolidone. Also disclosed is a method for enhancing the tran...
|
|
WO/2008/097546A2 |
Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a...
|
|
WO/2008/092786A1 |
The invention relates to 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives of Formula (I) wherein R 1, R 2 and R 3 are as defined herein, as γ-secretase inhibitors useful in the treatment of Alzheimer's disease or common cancer i...
|
|
WO/2008/093737A1 |
Disclosed is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a renin inhibitor. (I) wherein R1a represents a hydrogen atom, a C1-6 alkyl group which may be substituted, or the l...
|
|
WO/2008/081726A1 |
Disclosed is a process for producing an amide or a lactam in a simple manner and in high yield by allowing the rearrangement reaction of an oxime compound to proceed while preventing the production of a by-product such as ammonium sulfat...
|
|
WO/2008/075006A1 |
The invention provides compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, g, h and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharma...
|
|
WO/2008/070111A2 |
The present invention provides processes and intermediates for the preparation of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and salts thereof which are useful as serotonin-2C (5-HT2C) receptor agonists for the treatment o...
|
|
WO/2008/064887A1 |
The invention relates to a method for preparing an intermediate compound for a diisocyanate, comprising reacting a diamine represented by the formula H2N-(CH2)0-Y-(CH2)p-NH2 wherein Y is selected from CH(OX) or CH(COOX), o and p each are...
|
|
WO/2008/065681A2 |
The present invention provides a process for preparing Ivabradine of formula (I) or its pharmaceutically acceptable salts, solvates, hydrate thereof, by reacting 3-chloro-N-{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trie
n-7-yl]methyl}...
|
|
WO/2008/059513A2 |
Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmac...
|
|
WO/2008/055068A2 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein (B), Q, J, L and Z are as defined in the specification.
|
|
WO/2008/054609A2 |
An approach to designing families of cocrystals with desired (tunable) pH dependent dissolution is developed. The solubility and dissolution rate of a family of cocrystals with the same API and a series of ligands that are weak acids or ...
|
|
WO/2008/049808A1 |
The present invention is concerned with novel tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for prepar...
|
|
WO/2008/038053A1 |
Compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula(1) wherein A and B are CH2 or CH2CH2, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected fro...
|
|
WO/2008/038578A1 |
Disclosed are an optically active quaternary ammonium salt having axial asymmetry and a method for producing an α-amino acid and a derivative thereof by using the quaternary ammonium salt. The optically active quaternary ammonium salt h...
|
|
WO/2008/022945A1 |
The invention relates to compounds of the general formula (I) in which A, B, D, Y, R1, R2, R3, R4 and R5 are defined as per claim 1, to their enantiomers, their diastereomers, their mixtures and their salts, especially their physiologica...
|
|
WO/2008/019572A1 |
This invention belongs to pharmacy field. Meptazinol biligand derivatives,salts, preparation method and uses thereof in the treatment CNS degenerative diseases including Alzheimer's type and dementia. The method comprises crude materials...
|
|
WO/2008/012837A1 |
Disclosed herein is a process for producing 10-oxo-10,11-dihydro-5H-dibenz[bf] azepine-5-carboxamide of formula I via novel intermediates 11-alkoxy-10-halo-10,11-dihydro-5H-dibenzo [b,f ] azepine-5-carbonitrile [XIX] or 10-alkoxy-5H-dibe...
|
|
WO/2008/012524A1 |
The present invention relates to novel analine derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
|
|
WO/2008/009671A1 |
The invention relates to an improved process for the preparation of a tetrahydro-1H- azepine of formula (I) wherein R1 and R2 have the meaning given in the claims; by a ring closure metathesis of the corresponding diene of formula (II) i...
|
|
WO/2008/011539A2 |
In one embodiment the invention provides novel compounds of Formula (I) as well as prodrugs, salts, hydrates, solvates and N-oxides thereof. The invention also provides pharmaceutical compositions that include such compounds as well as m...
|
|
WO/2008/000131A1 |
The present application discloses a type of α-amino-N-substituted amide compounds, compositions and uses thereof. The present compounds are represented by general formula I. It is easy to prepare these compounds. These compounds have st...
|
|
WO/2007/149728A2 |
Aryl tetrahydrobenzazepine derivatives with minimal 5-HT2B activity relative to 5-HT2A and 5-HT2C activity that are useful for treating glaucoma are disclosed.
|
|
WO/2007/146838A2 |
Substituted phenyl acetic acid compounds of formula (I), pharmaceutical compositions, methods for their preparation and methods are provided that are useful in the treatment and prevention of disorders or conditions responsive to DP-2 re...
|
|
WO/2007/141798A1 |
Disclosed herein is an economically viable and cost effective process for preparation of oxcarbazepine of formula (I) via a novel intermediate of formula (XVIII).
|
|
WO/2007/139215A1 |
A method of the invention industrially produces heterocyclic mercapto compounds useful as raw materials or intermediates in the synthesis of medicaments or pesticides, or as permanent wave agent, with a high yield and high productivity u...
|
